Breaking AI & Tech News Analyzed

Wallace Shawn Confronts Skepticism About His ActingWallace Shawn acknowledges that many doubt his acting abilities, reflecting on a career often defined by his distinctive voice and character roles.Therapy as a Lifeline in a Demanding IndustryHe credits ongoing therapy for helping him navigate the pressures of Hollywood and maintain creative stamina.Advocacy for Palestine Amidst Hollywood ControversyShawn discusses his decision to speak out on Palestine, describing the personal and professional risks involved.What Lies Ahead for Shawn and the ConversationHe hints at future projects that may blend his artistic work with his activist stance, suggesting a continued push for both artistic and political dialogue.

The Personal Mission Behind the InvestmentReed Jobs, son of Apple co-founder Steve Jobs, is bringing his oncology-focused venture capital fund Yosemite to the UK, seeking investment opportunities in cancer care. The 34-year-old's mission is deeply personal, stemming from witnessing his father's death from a rare form of pancreatic cancer in 2011 at age 56. "I saw my dad have cancer when I was a kid, and unfortunately that happens far too often. And that really motivated me to try to transform outcomes for other people out there," Jobs explains.Yosemite's Healthcare Investment StrategyThe San Francisco-based venture fund, named after the California national park where his parents married, manages over $1 billion in assets and has already invested in approximately 20 healthcare startups. Yosemite focuses on innovative approaches to cancer treatment, including gene therapy, cancer vaccines, radiopharmaceuticals, and artificial intelligence. Notable investments include Tune Therapeutics, Azalea Therapeutics, Chai Discovery, and Sage Care in the US, with several UK companies in their portfolio that haven't been publicly announced.Financial Backing and International PartnershipsYosemite receives investment from LifeArc, a UK not-for-profit group focused on rare diseases that was established in 2000 as part of the UK's Medical Research Council. The fund also has partnerships with Oxford and Cambridge universities, where it has provided philanthropic grants. Additional backing comes from US biotech company Amgen, Massachusetts Institute of Technology, Memorial Sloan Kettering Cancer Center in New York, and billionaire investor John Doerr, following a fundraiser earlier this year.UK's Position in Global Cancer Research"Research here is world class," Jobs states during his visit to London for a life sciences conference hosted by LifeArc. The UK's strong academic institutions and research environment make it an attractive location for healthcare investment. Yosemite's international investment strategy includes the UK, where the fund aims to connect with pharmaceutical partners and academics to advance cancer treatment possibilities.Future Vision for Cancer TreatmentJobs envisions a future where cancer shifts from being an "end-stage disease" to an illness that is diagnosed early, monitored, and treated—similar to advances made with HIV and cardiovascular disease. "Today far too many cancers are either diagnosed incidentally, because there's no good early biomarker, or only diagnosed once they are metastatic and extremely advanced," he notes. The fund is particularly focused on immunotherapy, which Jobs identifies as "one of the areas I think is going to have the most promise for patients in the next couple of decades."

The Giant Pickle Parade Kicks Off the UK's First Jewish Culture MonthLondoners spotted a towering green pickle strolling past the Tate Modern, Southbank Centre and other iconic sites, delivering a simple message: the nation’s inaugural Jewish Culture Month has begun.150+ Events Across Museums, Libraries and Community HubsStarting on 16 May, the festival curated by the Board of Deputies of British Jews will feature more than 150 programmes covering food, music, comedy, architecture, fashion, film and literature.V&A MuseumNational Portrait GalleryJW3 (London’s Jewish community centre)British LibraryNational Holocaust MuseumScale of the Festival: Over 150 Programs and Nationwide ReachThe sheer volume of events underscores a coordinated effort to make Jewish culture visible across the UK, from London to Nottinghamshire. Highlights include a traditional Friday night dinner hosted by east‑London pickling firm Shedletsky, a punk‑themed exhibition at JW3, and walking tours by the Association of Jewish Refugees exploring historic Jewish sites outside the capital.Why the Celebration Matters Amid Rising AntisemitismLiat Rosenthal, director of culture, education and communities at the Board, explained that the month emerged from conversations with artists who felt Jewish life had become defined by hostility since the 7 October 2023 attacks in Israel. The initiative aims to replace “oy” with “joy”, inviting people of all backgrounds to learn, eat and engage.By foregrounding contributions in science, technology, psychotherapy, medicine and politics, organisers hope to shift public perception from victimhood to pride.Looking Ahead: Building Long‑Term Visibility for British JewryBeyond the month, the Board plans to leverage the momentum for sustained cultural programming and education. Success will be measured by increased attendance at Jewish‑focused events, broader media coverage and, ultimately, a measurable decline in antisemitic incidents reported during the festival period.

The LeadJennie Garth, known for her role as Kelly Taylor in 'Beverly Hills, 90210,' opens up about the psychological impact of early fame and how she found new purpose in her 50s. The 54-year-old actress, who felt 'stuck' and unfulfilled as her daughters grew up, has launched a podcast and book titled 'I Choose Me,' sharing her journey of self-discovery and the lessons learned from her decades in Hollywood.Finding Purpose at 50Approaching her 50s, Garth experienced a classic midlife crisis, questioning her path and purpose after noticing potential acting jobs becoming 'few and far between.' The deaths of her 90210 co-stars Luke Perry in 2019 and Shannen Doherty in 2024 intensified her sense of urgency, prompting her to share what she's learned with other women experiencing similar standstills. Her new venture, 'I Choose Me,' named after an iconic line from her character on the show, combines memoir and self-help as Garth reflects on her journey from teenage star to mature woman finding her voice.The Price of Early FameGarth candidly admits that her early fame 'screwed with her mind,' describing how she spent 20 years 'trying to keep her head above water.' Starting on the hit show at just 18, she felt developmentally 'held back from the realities of the world,' watching peers experience normal milestones while she was 'slammed into' fame. The experience left her questioning how her unusual path affected her relationships and personal growth, as she struggled to form normal connections while constantly being judged and typecast in the industry.Hollywood's Changing LandscapeThe actress reflects on the sexism she faced in the 90s, noting how young female actors were 'exposed to far more than they should' in terms of sexualization and discrimination. She recalls unspoken expectations about appearance and the pressure to conform to certain standards, including her own decision to get breast enhancement at 24. Garth also discusses how the industry typecast her and her co-stars, keeping them in a 'sort of Aaron Spelling-nighttime-soapy category' that limited their growth opportunities, despite the quality of their work.A New ChapterNow in her 50s, Garth feels she's finally 'caught up' developmentally and is embracing her age with greater wisdom and resilience. Through therapy and self-help, she's found a new voice and purpose, sharing her experiences to help other women navigate similar challenges. Her journey from teenage star to empowered woman reflects both the lasting impact of early fame and the potential for reinvention later in life, as she continues to work while also focusing on personal growth and helping others find their own path to self-acceptance.

Manchester City Women have moved into a purpose‑built, £10 million complex at the City Football Academy, featuring everything from personalised chopsticks to an underwater treadmill, and the upgrade is already paying dividends with a WSL title and an FA Cup final appearance.State‑of‑the‑art facility gives Manchester City Women a performance edgeThe 17,000 sq ft headquarters includes a barista‑style coffee machine, three chefs crafting bespoke recovery shakes, and a canteen where Japanese players receive individually engraved chopsticks. Players can test hamstring strength in a dedicated gym, use non‑invasive shock‑wave therapy, and unwind on an underwater treadmill while watching Sky Sports News.£10 million investment and 17,000 sq ft of purpose‑built spaceCost: £10 millionSize: 17,000 sq ftOpening date: 10 March 2026 (after the international break)Key amenities: gender‑specific gym equipment, specialist recovery drinks, personalised lockers, three‑chef canteenRaising the bar for women’s football infrastructure across the leagueClub captain Alex Greenwood hailed the hub as the best she’s seen, even compared to England’s St George’s Park. The facility follows Brighton’s £8.5 million centre and signals a shift toward dedicated women’s venues, potentially prompting other WSL clubs to invest similarly.What the next season could hold for City and the wider WSLWith a deep, youthful squad already in place, City’s managing director Charlotte O’Neill expects strategic summer signings rather than a wholesale overhaul. The new hub may also enable City to field an academy side in the Women’s National League from 2027, further strengthening the club’s talent pipeline and influencing league‑wide development.

A new large‑scale randomized trial presented at the European Congress on Obesity in Istanbul indicates that the oral GLP‑1 antagonist orforglipron can help patients retain the majority of weight lost with injectable therapies such as tirzepatide (Mounjaro) and semaglutide (Wegovy).Trial Shows Oral Orforglipron Preserves Most Weight After Switching from InjectablesThe study, funded by Eli Lilly, followed 376 US patients who had been on tirzepatide or semaglutide injections for 72 weeks and then randomized them to a daily orforglipron tablet or placebo for an additional year.Participants were previously on weekly GLP‑1 jabs that typically produce 15‑20% body‑weight loss.After the injection phase, subjects were switched to oral therapy or placebo for 12 months.Primary endpoint: proportion of weight loss retained at 12 months.Quantitative Outcomes: 75% vs 49% Retention for Tirzepatide Users, 80% vs 38% for Semaglutide UsersWeight‑loss maintenance differed markedly between the pill and placebo groups:Tirzepatide cohort: 75% of lost weight retained with orforglipron vs 49% with placebo.Semaglutide cohort: 80% retained with the pill vs 38% with placebo.Secondary benefits—blood pressure, cholesterol, and glycaemic control—were also sustained in the pill arm.Implications for Obesity Management and Healthcare CostsExperts highlighted the broader significance:Dr Louis Aronne (Weill Cornell Medicine) emphasized that treating obesity directly can simultaneously improve glucose, lipid, and blood‑pressure metrics.Dr Marie Spreckley (University of Cambridge) noted patient preference for oral therapy due to convenience, storage, and lower cost.Dr Simon Cork (Anglia Ruskin University) warned that injectable GLP‑1 drugs, while highly effective, are expensive and limit long‑term accessibility for both private payers and the NHS.The findings suggest a potential shift toward oral agents that maintain efficacy while reducing financial and logistical burdens.Future Outlook: Oral GLP‑1 Therapies Could Redefine Chronic Obesity CareIf further trials confirm these results, orforglipron could become a cornerstone of chronic obesity management, enabling earlier intervention (BMI 25‑27) and possibly preventing progression to severe obesity.Regulators and payers will likely scrutinize cost‑effectiveness models, but the prospect of a cheap, daily tablet that sustains weight loss may reshape treatment algorithms worldwide.

Trump’s Public Endorsement of Psychedelic TherapiesIn a recent Guardian podcast, Donald Trump signaled support for scientific studies into psychedelic compounds, asking, “Can I have some, please?” while framing the conversation as a potential public‑health breakthrough.Funding Landscape and Recent Regulatory Milestones2023: The U.S. Food and Drug Administration granted breakthrough‑therapy designation to psilocybin for treatment‑resistant depression.2024: The National Institute on Drug Abuse allocated $150 million to clinical trials of MDMA‑assisted psychotherapy.2025: Several states, including Oregon and Colorado, legalized psilocybin for therapeutic use, creating a nascent market valued at roughly $2 billion.Potential Shift in Federal Drug PolicyTrump’s backing could influence congressional committees that oversee the Drug Enforcement Administration and the FDA. A high‑profile endorsement may:Accelerate bipartisan bills aimed at de‑scheduling certain psychedelics.Encourage the administration to prioritize research funding in upcoming budget proposals.Prompt the White House to convene a task force on psychedelic medicine.Impact on Mental‑Health Treatment ParadigmsShould policy changes follow, clinicians could gain broader access to psychedelic‑assisted therapies, potentially reducing reliance on traditional antidepressants. This aligns with growing evidence that psychedelics can produce rapid, sustained improvements for conditions such as PTSD and major depressive disorder.Looking Ahead: Political and Clinical OutlookAnalysts anticipate that Trump’s endorsement will keep psychedelics on the national agenda through the 2026 midterm elections. If legislative momentum continues, the United States could see:A federal framework for clinical trials by 2027.Expanded insurance coverage for approved psychedelic treatments by 2028.Increased private‑sector investment, potentially adding $5 billion to the market over the next five years.

Why CAR T‑Cell Therapy Is Being Called a Game‑ChangerProf Misty Jenkins of the Walter and Eliza Hall Institute describes the therapy as a "game‑changer" because it re‑programs a patient’s own T‑cells to hunt cancer with unprecedented precision. The recent remission of Sam Neill after a Sydney trial has thrust the technology into the public eye, illustrating the potential of a single infusion to achieve durable responses. How the Therapy Works and Recent Clinical SuccessesCAR (chimeric antigen receptor) T‑cell therapy involves three core steps:Extracting a patient’s T‑cells from blood.Genetically engineering them to express a synthetic "GPS" that recognises cancer‑specific proteins.Expanding the modified cells and infusing them back, where they multiply and seek out tumours.Key milestones highlighted in the article:Four CAR T‑cell products approved by Australia’s Therapeutic Goods Administration since 2018, all for blood cancers.Early trials show promise against solid tumours such as gastrointestinal and paediatric brain cancers.In‑vivo approaches are being explored to deliver the therapy via injection, potentially slashing production costs. Cost, Approval Landscape and Funding Milestones in AustraliaCurrent price tag for a single CAR T‑cell course can exceed AU$500,000 per patient.The federal government announced that Carvykti for multiple myeloma will be provided free in public hospitals, a treatment that otherwise costs over AU$200,000.Four approved therapies since 2018 indicate a rapidly expanding regulatory environment, but access remains uneven across states. Implications for Australian Cancer Care and the Global Immunotherapy RaceThe success of CAR T‑cell therapy could reshape Australia’s oncology landscape by:Reducing relapse rates – the therapy can act as a "living drug" that persists in the body.Driving investment in domestic manufacturing capabilities, essential for sovereign supply and cost control.Positioning Australia as a leader in next‑generation immunotherapies, provided research funding keeps pace. What the Next Five Years May Hold for CAR T‑Cell TreatmentsExperts anticipate several developments:Broader approvals for solid‑tumour indications as GPS targeting becomes more precise.Commercial rollout of in‑vivo CAR T‑cell vaccines, potentially lowering treatment costs by an order of magnitude.Policy reforms to integrate CAR T‑cell therapy into standard public‑hospital pathways, ensuring equitable access.While optimism is high, Assoc Prof Maté Biro cautions that "hope is warranted, but so is impatience" – the next wave of breakthroughs will depend on sustained scientific investment and swift regulatory action.

The Harsh Reality of Motherhood in Gaza On May 10, many flowers and boxes of chocolates will be gifted to mothers in the United States, Canada, and elsewhere. However, in Gaza, 22,000 women have been killed in two and a half years, and many children dread this special day because it reminds them of intolerable pain. The Impact of Genocide on Gaza's Mothers The genocide has brought immense suffering to Gaza's mothers. Maternal death rates during childbirth increased threefold during the genocide, with 220 Palestinian women dying while giving birth in Gaza between January and June 2025. The famine has disproportionately affected pregnant and breastfeeding women, putting them and their children at risk of death and various health complications. The Personal Story of Struggle The author's mother, Najat, is suffering from cancer, which was diagnosed late. On Mother's Day, she did not wear her finest clothes and did not join the family for a special meal. She was frail and worn down after undergoing chemotherapy. The author silently prayed that her mother would remain with her a little longer, holding back tears to avoid adding to her mother's pain. The Burden of Survival More than 22,000 women have lost their husbands and are now forced to be both mothers and fathers to their children, carrying the excruciating task of survival amid a genocide. Many mothers have to live with the constant pain of losing their children in Israeli attacks; more than 21,000 of the victims of the genocide were children. The Lack of Medical Care Israel has made sure that Gaza's mothers are not getting the treatment they need. The Israeli army has bombed all hospitals in Gaza and destroyed the only specialized oncological hospital. This has meant that cancer and chronic illness patients are not receiving proper treatment, and regular checkups that can catch diseases in early stages are not possible. The Uncertain Future The author's mother needs radiation therapy, which is not available in Gaza. She has been given a medical referral, which has not been approved yet. She is one of 20,000 Palestinians in Gaza in urgent need of evacuation, which has been purposefully made brutally slow. The author's mother may not survive, and her suffering, along with that of many other Gaza mothers, will go unseen.